Myoma Uteri

myomauteri-1-0-25kapak

Relationship Between Myoma and Malignancy: Approach in Case of Incidental Sarcoma and STUMPs

Osman Türkmen

Ankara Yıldırım Beyazıt University, Faculty of Medicine, Department of Gynecology and Obstetric, Ankara, Türkiye

Türkmen O. Relationship Between Myoma and Malignancy: Approach in Case of Incidental Sarcoma and STUMPs. Yavuz AF, ed. Myoma Uteri. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.129-132.

ABSTRACT

Uterine sarcomas and smooth muscle tumors of uncertain malignant potential (STUMP) can be seen in women incidentally after myomectomy or after hysterectomy. Numerous studies have been conducted to distinguish sarcoma from myoma in the preoperative period. However, despite these studies, the desired level of myoma and sarcoma differentiation has not been achieved. In cases of incidentally detected sarcoma and STUMP, the most appropriate approach for the patient should be selected by taking into account the previous surgical method and the patient’s desire for fertility.

Keywords: Leiomyoma; Leiomyosarcoma; STUMP; Myomectomy

Referanslar

  1. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, et al., 3rd, National Comprehensive Cancer Network. Uterine Sarcoma, Version 1.2016: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2015:13(11),1321-1331. [Crossref]  [PubMed]
  2. Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, et al., Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkunde, 2015;75(10), 1028-1042. [Crossref]  [PubMed]  [PMC]
  3. Dinh TA, Oliva EA, Fuller AFJ, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecologic Oncology, 2004;92(2), 648-652. [Crossref]  [PubMed]
  4. Li D, Yin N, Du G, Wang S, Xiao Z, Chen J, Chen W. A Real-World Study on Diagnosis and Treatment of Uterine Sarcoma in Western China. International journal of biological sciences, 2020;16(3), 388-395. [Crossref]  [PubMed]  [PMC]
  5. Leibsohn S, d'Ablaing G, Mishell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. American journal of obstetrics and gynecology, 1990;162(4), 968-976. [Crossref]  [PubMed]
  6. Goto A, Takeuchi S, Sugimura K, Maruo T. Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 2024;12(4), 354-361. [Crossref]  [PubMed]
  7. Cho HY, Kim K, Kim YB, No JH. Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. The journal of obstetrics and gynaecology research, 2015;42(3), 313-318. [Crossref]  [PubMed]
  8. Peters A, Sadecky AM, Winger DG, Guido RS, Lee TTM, Mansuria SM, et al. Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society, 2017;27(6), 1183-1190. [Crossref]  [PubMed]  [PMC]
  9. Pritts EA, Vanness DJ, Berek JS, Parker W, Feinberg R, Feinberg J, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecological surgery, 12(3), 165-177. [Crossref]  [PubMed]  [PMC]
  10. Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, et al. An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. Journal of minimally invasive gynecology, 2016;23(3),303-308. [Crossref]  [PubMed]
  11. Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi, S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecologic oncology, 2017;145(1), 61-70. [Crossref]  [PubMed]
  12. Nasioudis D, Chapman-Davis E, Frey M, Holcomb K. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. Journal of gynecologic oncology, 2017;28(4), e46. [Crossref]  [PubMed]  [PMC]
  13. Lissoni A, Cormio G, Bonazzi C, Perego P, Lomonico S, Gabriele A, et al. Fertility-sparing surgery in uterine leiomyosarcoma. Gynecologic oncology, 1998;70(3), 348-350. [Crossref]  [PubMed]
  14. Ip PP, Cheung AN, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. The American journal of surgical pathology, 2009;33(7), 992-1005. [Crossref]  [PubMed]
  15. Ha HI, Choi MC, Heo JH, Kim KA, Jung SG, et al. A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution. European journal of obstetrics, gynecology, and reproductive biology, 2018;228,1-5. [Crossref]  [PubMed]
  16. Prayson RA, Goldblum JR, Hart WR. Epithelioid smooth-muscle tumors of the uterus: a clinicopathologic study of 18 patients. The American journal of surgical pathology, 1997;21(4), 383-391. [Crossref]  [PubMed]
  17. Ly A, Mills AM, McKenney JK, Balzer BL, Kempson RL, Hendrickson MR et al. Atypical leiomyomas of the uterus: a clinicopathologic study of 51 cases. The American journal of surgical pathology, 2013;37(5), 643-649. [Crossref]  [PubMed]
  18. Garg M, Rajanbabu A, Nair IR. Smooth muscle tumors of uncertain malignant potential or atypical leiomyomas: A long-term evaluation of surgical outcomes and clinicopathological features. European journal of obstetrics, gynecology, and reproductive biology, 2024;301, 201-205. [Crossref]  [PubMed]